Related Experiment Video
Updated: Jun 26, 2025
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and
Vinay Mathew Thomas1, Nicolas Sayegh2, Beverly Chigarira1
1Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Patients with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) show distinct gene expression profiles compared to those with prior local therapy (PLT-mCSPC). Understanding these genomic differences, particularly inflammation in dn-mCSPC, can personalize prostate cancer treatment.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Prostate cancer patients with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) often have poorer outcomes than those with metastasis after prior local therapy (PLT-mCSPC).
- The underlying molecular mechanisms contributing to these differing prognoses are not fully understood.
Purpose of the Study:
- To investigate and validate differences in tumor gene expression profiles between dn-mCSPC and PLT-mCSPC.
- To identify specific genomic pathways that distinguish these two patient groups.
Main Methods:
- RNA sequencing data from treatment-naïve primary prostate tissue of 128 eligible patients (78 in Tempus cohort, 50 in Caris cohort) were analyzed.
- Differential gene expression analysis was performed using the DEseq2 pipeline.
- Gene Set Enrichment analysis identified enriched pathways in each cohort.
Main Results:
- Tumor tissues from dn-mCSPC patients exhibited higher expression of genes associated with inflammation pathways.
- Tumor tissues from PLT-mCSPC patients showed higher expression of genes involved in oxidative phosphorylation, fatty acid metabolism, and androgen response pathways.
- Distinct genomic pathways were upregulated in dn-mCSPC compared to PLT-mCSPC.
Conclusions:
- The study identified significant differences in genomic pathways between dn-mCSPC and PLT-mCSPC.
- These findings provide a basis for hypothesis generation regarding personalized therapy strategies.
- Understanding these molecular distinctions may help explain the observed differences in survival outcomes for these prostate cancer patient groups.
